Navi acquisition not cleared by CCPC

RNS Number : 9160J

Uniphar PLC

16 December 2022

 

Navi acquisition not cleared by CCPC

Dublin, London | 16 December 2022: Uniphar plc today announces that the Irish Competition and Consumer Protection Commission ("CCPC") has not cleared the proposed acquisition of Irish-headquartered pharmacy services group Navi Group ("Navi").

Following the proposal to acquire Navi, which was announced on 23^rd December 2021, both Uniphar and Navi have engaged extensively with the CCPC and supported them in their review of the proposed transaction. However, the transaction will now no longer proceed to completion.

Navi has been a longstanding partner of Uniphar and both parties will continue to work closely together to support our shared customer base of independent community pharmacies.

For further details contact:

Uniphar [phone] Allan Smylie Head of Strategy and IR [e-mail] Davy (Joint Corporate Broker, Nominated Adviser and Euronext Growth Listing Sponsor) [phone] Barry Murphy Niall Gilchrist Lauren O'Sullivan RBC Capital Markets (Joint Corporate Broker) [phone] Jonathan Hardy Jamil Miah Stifel Nicolaus Europe Limited (Joint Corporate Broker) [phone] Matt Blawat Ben Maddison Francis North Q4 PR [phone] or (Public Relations Adviser to Uniphar) [phone] Iarla Mongey

About Uniphar plc 

Headquartered in Dublin, Ireland, the Uniphar Group is an international diversified healthcare services business servicing the requirements of more than 200 multinational pharmaceutical and medical technology manufacturers across three divisions - Commercial & Clinical, Product Access and Supply Chain & Retail. The Group is active in Ireland, the UK, Europe, the US and Australia.

The Company's vision is to improve patient access to pharmaco-medical products and treatments by enhancing connectivity between manufacturers and healthcare stakeholders. Uniphar represents a strong combination of scale, growth, and profitability.

Commercial & Clinical

In Commercial & Clinical, the Group provides outsourced sales, marketing & distribution solutions to multinational pharmaceutical and medical device manufacturers. Active in Ireland, the UK, Benelux, the Nordics, Germany and the US, the Group is growing with its clients to provide pan-European solutions, with a targeted service offering in the US. Uniphar has built fully integrated digitally enabled customer centric solutions that are supported by our highly experienced and clinically trained teams, leveraging our digital technology and insights which allows us to deliver consistently exceptional outcomes for our clients.

Product Access

In Product Access, the Group is growing two distinct service offerings: 1) "On Demand", which are pharmacy led solutions for sourcing and supplying unlicensed medicines to meet the needs of both retail and hospital pharmacists; and 2) "Exclusive Access", which are manufacturer led solutions for controlling the release of speciality medicines for specifically approved patient populations in agreed markets. The Group currently delivers product access solutions on a global basis.

Supply Chain & Retail

Uniphar is an established market leader in Ireland with c. 53% market share in the wholesale/hospital market, supported by a network of 381 owned, franchised and symbol group pharmacies. The business supports the diverse customer base through the provision of strong service levels coupled with innovative commercial initiatives. Supply Chain & Retail is an Irish only business for the Group, although the manufacturer relationships and infrastructure are also utilised for the benefit of the Commercial & Clinical and Product Access divisions

 

END

 

 

ACQGPGCWPUPPGRA